Cargando...
Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer
This study was conducted with the aim to investigate the feasibility of intermittent treatment with docetaxel chemotherapy for castration-resistant prostate cancer (CRPC). A total of 51 men with CRPC received docetaxel at 75 mg/m(2) every 3 weeks combined with oral dexamethasone 1.0-2.0 mg/day betwe...
Guardado en:
| Publicado en: | Mol Clin Oncol |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
D.A. Spandidos
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4360872/ https://ncbi.nlm.nih.gov/pubmed/25798258 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2014.469 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|